Arcutis Biotherapeutics Inc Provides Positive Atopic Dermatitis Program Updates Call Transcript
Good day, and thank you for standing by. Welcome to the Arcutis Biotherapeutics Atopic Dermatitis Updates Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker and then Eric, he's Head of Investor Relations, Eric McIntyre, you may begin.
Thank you, Tanya. Good morning, everyone, and thank you for joining our call this morning on the exciting data we've released recently across our atopic dermatitis program. The slides for today are available on the Investors section of our website. On the call this morning, we have Frank Watanabe, President and CEO; and Patrick Burnett, Chief Medical Officer; and we are also joined by Dr. Larry Eichenfield, Chief of Pediatric and Adolescent Dermatology at Rady's Children Hospital and Professor of Dermatology and Pediatrics at UC San Diego School of Medicine. I'd remind everyone quickly that we will be making forward-looking statements during this call and any of these
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |